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Abstract
Background: Protein aggregation is a hallmark of several neurodegenerative diseases including
Huntington's disease and Parkinson's disease. Proteins containing long, homopolymeric stretches
of glutamine are especially prone to form aggregates. It has long been known that the small protein
modifier, ubiquitin, localizes to these aggregates. In this report, nematode and cell culture models
for polyglutamine aggregation are used to investigate the role of the ubiquitin pathway in protein
aggregation.
Results:  Ubiquitin conjugating enzymes (Ubc's) were identified that affect polyglutamine
aggregates in C. elegans. Specifically, RNAi knockdown of ubc-2 or ubc-22 causes a significant
increase in the size of aggregates as well as a reduction in aggregate number. In contrast, RNAi of
ubc-1, ubc-13, or uev-1  leads to a reduction of aggregate size and eliminates ubiquitin and
proteasome localization to aggregates. In cultured human cells, shRNA knockdown of human
homologs of these Ubc's (Ube2A, UbcH5b, and E2-25K) causes similar effects indicating a
conserved role for ubiquitination in polyglutamine protein aggregation.
Conclusion: Results of knockdown of different Ubc enzymes indicate that at least two different
and opposing ubiquitination events occur during polyglutamine aggregation. The loss of ubiquitin
localization after ubc-1, ubc-13, or uev-1 knockdown suggests that these enzymes might be directly
involved in ubiquitination of aggregating proteins.
Background
In the cell, misfolded proteins are usually degraded. In
some cases, when a misfolded protein is not efficiently
removed from the cell, protein aggregation will occur.
Aggregation occurs in neurodegenerative diseases such as
Huntington's disease, Parkinson's disease, Alzheimers dis-
ease, amyotrophic lateral sclerosis (ALS), spinobulbar
muscular atrophy, dentatorubral-pallidoluysian atrophy,
Prion diseases, spinocerebellar ataxias and others [1]. In
these diseases, aggregation largely correlates with cell dys-
function and cell death. The role that protein aggregation
plays in the damage that occurs in neurodegenerative dis-
eases is not completely clear. It appears that aggregation
itself is harmful because the expression of aggregating
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peptides in transgenic mice can lead to neurodegenerative
symptoms [2,3]. However, additional evidence suggests
that the aggregates themselves may be protective and that
the soluble mutant protein fragments might be toxic [4,5].
Several models have been proposed to explain the toxicity
of aggregating proteins including impairments of tran-
scription [6], protein degradation [7], protein trafficking
[8], or protein folding [9].
The precise molecular pathway leading to aggregation is
not well-known. Structural studies on aggregating poly-
glutamine proteins indicate that they adopt a β-sheet crys-
talline conformation characteristic of amyloid fibrils [10].
Aggregation is typically considered to be an unfavorable
activity for proteins and, indeed, there are mechanisms to
prevent such aggregation. Molecular chaperones seem to
prevent the formation of protein aggregates in the cell.
Overexpression of chaperone proteins can lead to a
decrease in the amount of aggregation [11]. Poly-
glutamine models in the nematode, C. elegans, have indi-
cated that expression of polyglutamine proteins is toxic
and that chaperones as well as other proteins can serve to
ameliorate that toxicity [12-15].
Early in the study of the protein aggregation phenome-
non, it was observed that the small protein, ubiquitin,
becomes concentrated at sites of aggregation [16]. Since
the initial discovery of ubiquitin in aggregates, it has been
found in almost every case of aggregation-related neuro-
degenerative diseases [1,17]. The nature of the ubiquitin
present in the aggregates is unknown. It is generally pre-
sumed that ubiquitin is conjugated onto substrate pro-
teins such as the aggregating protein itself or other
proteins that colocalize to aggregates. In fact, there is some
evidence that aggregating proteins are ubiquitinated
[18,19]. However, it is also possible that ubiquitin is
present in its monomeric state, or coupled with enzymes
of the ubiquitination pathway such as E1, E2, or E3
enzymes.
Proteasomes also localize to protein aggregates in the
aforementioned diseases [20]. Although it has been
shown numerous times that ubiquitin and proteasomes
colocalize to aggregates, the role that either plays in aggre-
gation has not been elucidated. Since aggregated proteins
are somewhat resistant to proteolysis [21,22], it is possi-
ble that the aggregating proteins are tagged for degrada-
tion by ubiquitin, but not degraded, thus concentrating
ubiquitin and proteasomes at sites of aggregation. Ubiq-
uitin has many functions in the cell aside from tagging
proteins for degradation. It can serve as a modulator of
protein trafficking, DNA repair, transcription, etc. [23].
Thus, the role of ubiquitination in protein aggregation
need not be restricted to the degradative pathway.
Ubiquitin becomes linked to other proteins via an isopep-
tide bond between the C-terminal glycine of ubiquitin
and a lysine side chain on the modified protein. Ubiquiti-
nation occurs via a conserved, three-step process involv-
ing the E1, E2 and E3 components of the pathway [24,25].
The E1 ubiquitin activating enzyme first interacts with
ubiquitin using an ATP-dependent mechanism to form a
thiolester linkage between a cysteine residue on the E1
and the C-terminal glycine of ubiquitin. Ubiquitin is sub-
sequently transferred from the E1 to a cysteine residue on
the E2 ubiquitin conjugating enzyme (Ubc). Next, the E3
ubiquitin ligases become involved in the process. The E3s
are a diverse class of proteins and they can function in the
pathway in one of two ways. Some E3s, such as the HECT
domain E3s, form a thiolester linkage with ubiquitin and
then subsequently transfer ubiquitin onto the target pro-
tein. In contrast, the more abundant E3s, such as the
RING domain E3s, do not act as true enzymes, but rather
function as a scaffold, interacting with both the target pro-
tein and the Ubc, thus allowing transfer of ubiquitin from
the Ubc onto the target protein. Ubiquitination can occur
in the form of monoubiquitination (addition of a single
ubiquitin) or polyubiquitination (addition of a chain of
ubiquitins).
In order to investigate the role of ubiquitination in pro-
tein aggregation, we have used a transgenic nematode sys-
tem as well as cultured human cells. The transgenic worm
strain expresses GFP fused to a stretch of 82 glutamines
(Q82:GFP). This strain of nematodes has large fluorescent
aggregates in the body wall muscles of larvae and adults
[12]. A similar strain was used to screen for genes that
affect the timing of aggregate accumulation [26]. That
screen identified the ubiquitin activating enzyme (uba-1)
as an important polyglutamine regulator. Our results
show that perturbation of ubiquitin conjugating enzymes
via RNAi has a significant effect on aggregate size and
number. Specifically, in nematodes, RNAi of the ubc-2 or
ubc-22 genes reduces the number but increases the size of
aggregates. RNAi of ubc-1 or ubiquitin itself increases the
number but decreases the size of aggregates. In HEK293
cultured cells, shRNA knockdown of the human
homologs of these Ubc genes shows similar effects on
aggregates, indicating a conserved function for these
enzymes. Because there are two different phenoptyes
observed upon knockdown of different Ubc enzymes, this
suggests that there are at least two separate ubiquitination
events that occur in the formation or metabolism of aggre-
gates.
Results
The RNAi technique was used to knockdown ubiquitina-
tion enzymes in cells expressing polyglutamine proteins.
The nematode, C. elegans, has 22 different Ubc's and 4
Uev's (ubiquitin conjugating enzyme variants) encodedBMC Cell Biology 2007, 8:32 http://www.biomedcentral.com/1471-2121/8/32
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in its genome [27]. Using available cDNA clones for
eleven of the Ubc's and two of the Uev's, we performed an
RNAi screen of these enzymes.
A nematode model system indicates Ubc's are involved in 
protein aggregation
A worm model for polyglutamine protein aggregation was
developed by Saytal et al. [12] and later converted into an
integrated strain as described [15]. This strain of worms
expresses GFP that has been fused to 82 glutamines. The
unc-54 promoter is used to drive expression of this fusion
protein, resulting in expression in body wall muscle cells
of the worm. We refer to this strain of worms as the
Q82:GFP strain.
Worms from the Q82:GFP strain were subjected to RNAi
of various Ubc's as well as ubiquitin (ubq-1) and a protea-
some subunit (rpt-1). Following RNAi, worms were fixed
and analyzed with respect to the number and size of GFP
aggregates. Figure 1 shows the results of the RNAi treat-
ments. In these experiments, embryos were collected from
gravid adults and then placed directly onto RNAi feeding
plates. Thus, exposure to the dsRNA began as soon as
these L1 larvae hatched from the egg shell.
RNAi of most Ubc's did not cause a discernable difference
in aggregate size or number, however, Figure 1 shows that
knockdown of ubc-2 and ubc-22 resulted in a significant
reduction in the number of aggregates per worm and an
increase in the average size of aggregates. Knockdown of
ubc-1, ubc-13, uev-1, and ubq-1 resulted in a reduction in
the size of aggregates. RNAi of ubc-1 and ubq-1 also caused
an increase in the number of aggregates. No other pheno-
types in these worms were noticed besides a marked
growth arrest and immobility in the ubq-1 and rpt-1 RNAi
worms after 48 hours.
Because ubc-1 showed an opposite phenotype from ubc-2
and ubc-22, this suggests that there are at least two differ-
ent ubiquitination events and that these different ubiqui-
tinations may have separate effects on the formation or
metabolism of the aggregates. RNAi of ubq-1, a gene
encoding a polyprotein consisting of 11 ubiquitin pep-
tides, was used to knockdown ubiquitin levels. Although
the phenotype with ubq-1 RNAi is severe [28], it may not
completely eliminate ubiquitin as there is a second gene,
ubq-2, which also encodes ubiquitin. RNAi knockdown of
ubq-1 showed a phenotype similar to that of ubc-1, sug-
gesting that the UBC-1 mediated ubiquitination event is
more prevalent or proceeds ubiquitination by UBC-2 or
UBC-22.
Further evidence for the epistasis of ubc-1 came from com-
bined RNAi experiments. When ubc-1 was knocked down
in combination with ubc-2, or ubc-22, the ubc-1 phenotype
was observed (Figure 1D). RT-PCR confirmed knockdown
of both ubc-1 and ubc-2 in the combined RNA treatments
(Figure 1E). The results from the combined RNAi experi-
ments are consistent with a model where ubc-1 functions
first in the cascade leading to ubiquitination of aggregat-
ing proteins.
The Ubc phenotype does not affect the solubility or 
amount of Q82:GFP
There are several possible scenarios to explain how knock-
down of Ubc's might affect the size and number of aggre-
gates. First, the resulting Ubc deficiency could affect the
total amount of Q82:GFP protein in the cell. Second, the
solubility of Q82:GFP could be altered. Third, the compo-
sition or density of the aggregate could be affected.
In order to test the first of these three possibilities, we
examined levels of Q82:GFP using western blot analysis
(Figure 2A). GFP is detected as a doublet that migrates in
the gel to a molecular weight of approximately 33–36
kDa. This weight agrees with the predicted weight of the
Q82:GFP fusion protein (37 kDa). The nature of the dif-
ference between the two bands in the doublet is
unknown. However, there does appear to be some varia-
tion in the relative abundance of the two species in some
RNAi samples. Future studies will address the significance
of these differences. The difference in molecular weight
between the two species is too small to be explained by
differences in ubiquitination and is more likely to be the
result of a smaller modification such as phosphorylation.
Quantitative analysis of the levels compared to an actin
control show that the absolute levels of Q82:GFP are not
significantly altered by the RNAi treatments. Therefore,
the differences in aggregate size and number that are seen
in RNAi of ubc-1, ubc-2, ubc-22, ubc-13, and uev-1 are most
likely not explained by changes in the expression or stabil-
ity of the Q82:GFP protein.
Differences in aggregate size and number could also be
explained by changes in the solubility of the poly-
glutamine proteins. This has been observed in several
instances. For example, overexpression of chaperone pro-
teins can increase the solubility of polyglutamine proteins
and reduce aggregation [15,29]. As a simple test for solu-
bility, we analyzed the amount of soluble GFP in images
of live worms, either RNAi treated or control (Figure 2B).
Some soluble GFP is observed in Q82:GFP worms at this
stage. However, there is no apparent change in the solubil-
ity upon any of the RNAi treatments. In contrast, exami-
nation of a strain containing a stretch of only 19
glutamines fused to GFP (Q19:GFP) clearly shows soluble
GFP (diffuse green fluorescence).BMC Cell Biology 2007, 8:32 http://www.biomedcentral.com/1471-2121/8/32
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Knockdown of ubc-1, ubc-13, or uev-1 affects localization 
of ubiquitin and proteasome to aggregates
The knockdown of certain Ubc's has an effect upon aggre-
gate size or numbers. Therefore, we wanted to test
whether ubiquitin localization to aggregates is affected.
Worms were subjected to RNAi, then, fixed and probed
with antibodies to either ubiquitin or a proteasome subu-
nit. Figure 3 shows the results of the colocalization exper-
iments. Staining of the control worms shows that both
ubiquitin and proteasome are localized to aggregates.
Knockdown of ubiquitin results in the removal of ubiqui-
tin as well as proteasomes from aggregates. This result sug-
RNAi of Ubiquitin Conjugating Enzymes in C. elegans Figure 1
RNAi of Ubiquitin Conjugating Enzymes in C. elegans. The Q82:GFP strain of C. elegans expresses polyglutamine aggre-
gates in body wall muscle cells. Synchronized worms from the Q82:GFP strain were treated with RNAi for 48 hours until they 
reached approximately the L4 larval stage. RNAi treatments included the knockdown of ubiquitin (ubq-1), a subunit of the pro-
teasome (rpt-1) and 11 different ubiquitin conjugating enzymes. Worms continue to express aggregates after these RNAi treat-
ments, however, significant alterations in numbers and sizes of aggregates occur upon knockdown of specific Ubc's. A) 
Fluorescent images of control and RNAi treated worms showing the Q82:GFP aggregates. Scale bar is 100 μm. B) The average 
number of aggregates was counted manually under 40× magnification. RNAi knockdown of ubiquitin (ubq-1), proteasome (rpt-
1) or ubc-1 resulted in an increase in the number of aggregates whereas RNAi of either ubc-2 or ubc-22 showed a significant 
decrease in the number of aggregates. (* indicates statistical significance at p < .05). C) The average size of aggregates was 
determined following knockdown of each Ubc after 48 hours of RNAi treatment. The control was found to have an average 
aggregate area of 2.23 μm2. Knockdown of ubq-1, ubc-1, or uev-1 resulted in a significant decrease in aggregate sizes. Knock-
down of rpt-1, ubc-2 or ubc-22 resulted in a significant increase in aggregate sizes. (* indicates statistical significance at p < .05). 
D) Same procedure as in A except that bacterial feeding cultures were combined to achieve knockdown of more than one 
Ubc. The ubc-1 phenotype is epistatic to both ubc-2 and ubc-22. There is no additive effect between ubc-2 and ubc-22. (* indi-
cates statistical significance at p < .05). E) RT-PCR of RNAi treated worms confirms RNAi knockdown. Primers for ubc-1, ubc-
2, and act-1 were used to test RNA levels after RNAi treatments. For each set of primers, PCR template for lane C is cDNA 
from control (pL4440) worms, lane 1 ubc-1(RNAi), lane 2 ubc-2(RNAi), and lane 1+2 ubc-1 + ubc-2(RNAi).
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gests that ubiquitin localization to aggregates may be
required for proteasome localization. Proteasome locali-
zation, however, is not required for localization of ubiq-
uitin to aggregates since ubiquitin still localizes to
aggregates after rpt-1 RNAi.
RNAi of ubc-1, ubc-13 and uev-1 all resulted in smaller
aggregates. Interestingly, these RNAi treatments also
showed decreased localization of ubiquitin to aggregates.
In addition, proteasome localization was abrogated in
these knockdowns (Figure 3), consistent with the hypo-
thesis that ubiquitin localization is a prerequisite for pro-
teasome localization. Loss of ubiquitin from aggregates
after knockdown of ubc-1, ubc-13 or  uev-1  cannot be
explained solely by the decrease in size since even smaller
aggregates in control worms also stain positively with the
ubiquitin and proteasome antibodies (Figure 3, top row).
Knockdown of ubc-2 or ubc-22, which both showed a dra-
matic increase in aggregate size, shows no effect on local-
ization of ubiquitin or proteasome. Since ubiquitin
localization is unaffected by RNAi of ubc-2 or ubc-22, it is
less likely that either of these Ubc's is involved in directly
ubiquitinating aggregate proteins. ubc-1, ubc-13, and uev-1
are more likely candidates for enzymes involved in ubiq-
uitinating aggregate proteins.
RNAi treatments do not affect Q82:GFP solubility or overall levels Figure 2
RNAi treatments do not affect Q82:GFP solubility or overall levels. The solubility and amount of Q82:GFP proteins 
were tested after RNAi treatment. A) Levels of Q82:GFP protein were analyzed with western blots using an antibody to GFP. 
The antibody detects GFP in transgenic strains but not in the wild type, N2, strain. The total levels of GFP (both bands of the 
doublet) were quantified using densitometry and adjusted based on the relative levels of actin as ascertained by reprobing the 
blot with anti-actin. The relative levels of GFP based on that analysis are given at the bottom. B) Worms were assessed for 
changes in Q82:GFP solubility after RNAi treatment for 24 hours. All worms, including the control, have a low level of soluble 
GFP that is apparent. Aggregates appear as bright green foci. No obvious differences in solubility are apparent between RNAi 
treatment and the control. The Q19:GFP strain is used to show the distribution of soluble GFP protein.
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Ubiquitin and proteasome colocalization to aggregates is affected by Ubc knockdown Figure 3
Ubiquitin and proteasome colocalization to aggregates is affected by Ubc knockdown. Antibodies to ubiquitin and 
a proteasome subunit were used to test the effects of Ubc RNAi. Yellow color in the Merge columns indicates colocalization 
with aggregates. In control worms, ubiquitin and proteasomes colocalize to polyglutamine aggregates (top row). RNAi with 
ubq-1 eliminates localization of both ubiquitin and proteasomes. RNAi with rpt-1 does not disrupt localization of ubiquitin to 
aggregates, but does remove proteasomes, as expected. RNAi with either ubc-1, ubc-13, or uev-1 diminishes localization of 
ubiquitin and proteasomes to aggregates, whereas ubc-2 and ubc-22 show no effect on colocalization.BMC Cell Biology 2007, 8:32 http://www.biomedcentral.com/1471-2121/8/32
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Human Ubc's have a similar affect on polyglutamine 
aggregation
Our results in C. elegans suggest that ubiquitination plays
an important role in the aggregation pathway. In order to
investigate whether this might also be true in human cells,
we performed shRNA experiments in HEK293 cells.
The worm genes showing the most dramatic phenotypes
included ubc-1, ubc-2 and ubc-22. We searched for human
orthologs of these Ubc's and identified two very close
orthologs of ubc-1 and ubc-2: Ube2A and UbcH5b, respec-
tively. The human and worm enzymes are extremely sim-
ilar with Ube2A and UBC-1 showing 84% identity and
UbcH5b and UBC-2 having 94% identity. There was no
close ortholog for ubc-22, however E2-25K (also known as
HIP2) was the closest human enzyme with 32% identity.
E2-25K is a well studied Ubc enzyme and many activities
have been attributed to it such as polyubiquitin chain syn-
thesis, cyclization of ubiquitin chains, neddylation, NF-
κB processing, and interaction with Huntingtin [30-33].
Although E2-25K and UBC-22 show a relatively low level
of identity, they both contain a C-terminal UBA or ubiq-
uitin associated domain as does Ubc1 of yeast.
shRNA plasmids for the human orthologs were used to
knockdown Ubc levels in HEK293 cells. Two different
shRNA constructs were used for each gene. shRNA plas-
mids were transfected together with a plasmid expressing
Q81:YFP. Control and shRNA treated cells are shown in
Figure 4A. Knockdown of the Ubc's was confirmed by
western blot (Figure 4B).
After transfection, cells were examined for the size of
aggregates as well as the number of aggregates per cell.
Knockdown of Ube2A, the UBC-1 homolog, resulted in a
decrease in the average size of aggregates (Figure 4C). In
addition, more cells overall had aggregates and a greater
percentage of cells had multiple aggregates (Figure 4D).
These results are consistent with the effect of ubc-1 RNAi
in worms. Therefore, the role that this enzyme plays in
aggregate formation or metabolism is conserved.
Knockdown of UbcH5b, the UBC-2 homolog, resulted in
a significant increase in the size of aggregates but did not
affect the number of aggregates per cell (Figure 4C &4D).
E2-25K (HIP2) is the Ubc that showed the lowest hom-
ology with its worm counterpart, UBC-22. E2-25K
showed a modest affect on aggregate size and no affect on
numbers of aggregates per cell. The RNAi phenotypes of
UbcH5b and E2-25K suggest that any ubiquitination
event(s) mediated by these enzymes somehow limits the
size of aggregates.
Human Ube2A and UbcH5b localize to aggregates
Antibodies to the human Ubc's were used to probe cells
expressing Q81:YFP. Figure 5 shows the localization of the
Ube2A, UbcH5b and E2-25K in HEK293 cells with poly-
glutamine aggregates. Ube2A and UbcH5b both show
strong colocalization to aggregates, whereas E2-25K does
not colocalize.
Ube2A is a closely related human ortholog of the worm
protein UBC-1. Although we do not know the subcellular
localization of UBC-1 in worms, we have shown that
UBC-1 affects ubiquitin localization to aggregates. Thus, it
is not surprising to find that Ube2A localizes to aggre-
gates. On the other hand, UBC-2, the worm ortholog of
UbcH5b, did not affect ubiquitin localization. Therefore,
it is curious that it would localize to aggregates. Perhaps it
is involved in a minor ubiquitination event on aggregate
proteins. Alternatively, UBC-2 might localize to aggre-
gates due to the high concentration of ubiquitin and pro-
teasomes that are present there.
Discussion
It has long been known that the small protein modifier,
ubiquitin, localizes to the large protein aggregates that
form in several types of neurodegenerative diseases. We
have investigated the role that ubiquitin plays in the for-
mation or metabolism of these aggregates by performing
knockdown of Ubc enzymes in the ubiquitination path-
way. Our results indicate that ubiquitination plays an
important role in polyglutamine protein aggregation.
Ubiquitination may have multiple roles in protein 
aggregation
Knockdown of Ubc's caused changes in the size or
number of polyglutamine protein aggregates. Our results
indicate that there are, at minimum, two different ubiqui-
tination events that affect aggregates. This conclusion is
made because there are two groups of phenotypes with
opposite characteristics: one set of knockdowns showing
larger and less numerous aggregates, and one set showing
smaller aggregates. Therefore, these two proposed ubiqui-
tination pathways appear to have opposing affects on
aggregation. A model for how the Ubc's might be involved
in protein aggregation is presented in Figure 6.
Both ubc-2 and ubc-22 had a similar phenotype: reduction
of aggregate number and increase in aggregate size. This
indicates that these two ubiquitinating enzymes may be
involved in a common process that limits the size of
aggregates. It is possible that ubiquitination by ubc-2 and
ubc-22 is important for degrading aggregating proteins or
for ridding the cell of aggregates that reach a certain size.
However, removal of aggregates does not seem a likely
mechanism for ubc-2 and ubc-22, since their knockdown
results in fewer aggregates than normal. Therefore, ubc-2BMC Cell Biology 2007, 8:32 http://www.biomedcentral.com/1471-2121/8/32
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and ubc-22 may be involved in limiting the coalescence of
smaller aggregates into larger aggregates.
Since they have the same knockdown phenotype and the
combined knockdown is not additive (Figure 1D), the
two enzymes, UBC-2 and UBC-22, might participate in
the same ubiquitination pathway or might function as a
dimer. There is evidence from both in vitro and in vivo
studies suggesting the existence of Ubc dimers and Ubc-
Uev dimers [34,35]. One interesting aspect of UBC-22 is
that it has a non-canonical catalytic site with an awk-
wardly placed cysteine residue in a context lacking all con-
Ubc knockdown affects polyglutamine aggregation in HEK293 cells Figure 4
Ubc knockdown affects polyglutamine aggregation in HEK293 cells. Knockdown of ubiquitin conjugating enzymes in 
HEK293 cells was achieved using short hairpin RNA plasmids (shRNA). HEK293 cells were transfected with Q81:YFP plasmid 
plus either control or Ubc shRNA plasmids. Two different shRNA constructs were used for each Ubc (designated as 1 and 2 
in panels B-D). Cells were allowed to grow for 72 hrs after transfection. A) Following incubation, RNAi silenced cells were 
imaged by fluorescence microscopy. The pictures shown are an overlay between a bright field and a fluorescent image. B) 
Western blotting was performed to detect the level of knockdown of each Ubc using the antibodies indicated. All shRNA con-
structs achieved significant knockdown of their cognate Ubc. C) Aggregate size was measured after Ubc RNAi. Ube2A knock-
down leads to smaller Q81:YFP aggregates however, UbcH5b and E2-25K knockdown increase the size of aggregates. At least 
150 aggregates were measured for each shRNA transfection. These data represent the average sizes of aggregates from three 
independent experiments (> 450 aggregates). D) The number of aggregates per cell after Ubc RNAi was determined by analyz-
ing photomicrographs of transfected cells. In control cells, approximately 42% of cells contain only soluble GFP and no aggre-
gates. Ube2A knockdown causes a higher percentage of cells to form aggregates and also results in an increase in the 
percentage of cells with more than one aggregate. Knockdown of UbcH5b or E2-25K does not alter the ratio of cells contain-
ing aggregates versus cells with soluble GFP. Nor do they significantly affect the average number of cells per aggregate. Data 
were obtained from three independent experiments, counting 150 cells each time.
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sensus residues [36]. Thus, it is possible that UBC-22 may
not be catalytically active as a Ubc enzyme but rather part-
ners with another functioning Ubc.
ubc-1, ubc-13, and uev-1 all showed a reduction in the size
of aggregates. This reduction in size came without a reduc-
tion in the overall levels or a change in solubility of
Q82:GFP protein. RNAi of ubc-1 had the most dramatic
effect on size and also caused aggregates to be more
numerous. UBC-1 could be involved in the process of
smaller aggregates joining together into larger aggregates
(Figure 6).
Since RNAi of ubc-1, ubc-13 and uev-1 all cause a reduction
in aggregate size and loss of ubiquitin from aggregates, it
is tempting to speculate that these enzymes might also
function in the same pathway. In fact, it has been shown
that the yeast homologs of these three enzymes function
together in ubiquitination of PCNA. Rad6, the yeast
homolog of ubc-1, is responsible for adding the initial
ubiquitin molecule onto PCNA, and the ubiquitin chain
is subsequently extended by the Ubc13/Uev1 dimer [37].
Knockdown of ubc-1, ubc-13 or uev-1 could cause aggre-
gates to be smaller due to a decrease in overall bulk of the
aggregate. Along with many other proteins, it is known
that the proteasomes localize to aggregates and, thereby,
could contribute to aggregate volume. Proteasome locali-
zation is disrupted after RNAi of ubc-1, ubc-13, or uev-1.
Therefore, one possible scenario is that ubiquitination of
Q82:GFP or some other protein attracts proteasomes to
the aggregate. In the absence of that ubiquitination, pro-
teasomes or other ubiquitin binding structures do not
colocalize and thus the overall size of the aggregate is
reduced.
The ubiquitination pathway is conserved
We have used the nematode as a model for understanding
the aggregation of polyglutamine proteins. The validity of
this model was tested by examining the effects of Ubc
RNAi in human cells expressing polyglutamine aggre-
gates. Our results indicate that both worm cells and
human cells deal with polyglutamine proteins using a
conserved mechanism.
A model for the role of Ubc's in the formation of poly- glutamine aggregates Figure 6
A model for the role of Ubc's in the formation of pol-
yglutamine aggregates. In our experimental system, Ubc's 
are required for polyglutamine aggregates to achieve their 
normal size. Other research has indicated that aggregates ini-
tiate as small particles of aggregating protein that then travel 
along microtubules to ultimately collect and form large 
aggregates [42]. Since the knockdown of ubc-1 results in 
smaller, more numerous aggregates, ubiquitination by ubc-1 
may be needed for small aggregates to come together and 
form large aggregates. UBC-2 and UBC-22 may normally 
have an inhibitory role in this process because their knock-
down results in larger and less numerous aggregates. Ubiqui-
tination by ubc-13 and uev-1 may be required to recruit other 
proteins, such as proteasomes, to the aggregates, thereby 
allowing aggregates to further increase in size.
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Ube2A and UbcH5b localize to aggregates Figure 5
Ube2A and UbcH5b localize to aggregates. The locali-
zation of Ubc's in cells containing polyglutamine aggregates 
was determined by immunofluorescence. HEK293 cells were 
cultured in 24 well plates, fixed and immunostained with anti-
bodies against Ube2A, UbcH5b and E2-25K proteins. Con-
trol slides lacked primary antibody. Approximately 150 cells 
per Ubc enzyme were observed. To quantify colocalization, 
the percent of cells which contained YFP aggregates that also 
stained with the Ubc antibody was determined. In Ube2A 
and UbcH5b there was partial localization (49% and 71% 
respectively) whereas E2-25K showed no distinct colocaliza-
tion with aggregates.
GFP Antibody               Merge
No antibody
Ube2A
UbcH5b 
E2-25KBMC Cell Biology 2007, 8:32 http://www.biomedcentral.com/1471-2121/8/32
Page 10 of 12
(page number not for citation purposes)
Using shRNA plasmids, we achieved knockdown of three
human Ubc's that have homologs in our group of worm
Ubc's with strong effects on aggregates. The human Ubc's
with strong similarity to the worm enzymes showed phe-
notypes that mimicked the RNAi phenotype in worms.
E2-25K, which has only weak identity to worm UBC-22,
showed a less pronounced aggregate phenotype.
Conclusion
Using model systems, we have shown that knockdown of
certain Ubc's can lead to changes in polyglutamine aggre-
gates either in nematodes or human cells. However, the
mechanism whereby ubiquitination affects protein aggre-
gation remains unknown and could be either a direct or
indirect affect of Ubc knockdown. The result that knock-
down of ubc-1, ubc-13, and uev-1 reduce ubiquitin locali-
zation to aggregates favors a model where these enzymes
participate directly in ubiquitinating components of the
aggregate. It will be important to learn the targets for ubiq-
uitination and to determine which Ubc's and ubiquitin
ligases are involved in ubiquitinating those targets.
Methods
Worm strains and maintenance
Worms were maintained at 20°C on nematode growth
media with OP50 E. coli according to standard methods
[38]. The integrated Q82:GFP nematode strain is
described elsewhere [15]. The OP50 and HT115 bacterial
strains as well as N2 worms were obtained from the
Caenorhabditis Genetics Center.
Plasmid constructions
The GATEWAY system (Invitrogen, Inc.) and the vector
pL4440GTWY [39] were used to generate RNAi feeding
plasmids [40]. RNAi clones for ubc-1, ubc-2, ubc-7, ubc-8,
ubc-13, ubc-14, ubc-16, ubc-20, ubc-22, ubc-24, uev-1, uev-2,
ubq-1, and rpt-1 were made using recombinational clon-
ing with pL4440GTWY and entry clones obtained from
Mark Vidal and Open Biosystems, Inc. [41].
For aggregate expression in HEK293 cells, the Q81-YFP
plasmid was generously provided by Dr James R. Burke
(Duke University Medical Center Durham, NC). Expres-
sion Arrest™ human shRNA plasmids were from Open
Biosystems. Expression Arrest™ contained either the non-
silencing sequence which has no homology in mammals
(control) or sequences specifically targeting Ube2A (1,
RHS1764-9391619; 2, RHS1764-9690190), UbcH5b (1,
RHS1764-9392787; 2, RHS1764-9685283), or E2-25K (1,
RHS1764-9700185; 2, RHS1764-9100963).
Nematode RNAi
RNAi was performed as previously described [39]. Plas-
mids described above were transformed into HT115 E.
coli. 35 mm NGM plates were supplemented with 1 mM
isopropyl-β-thiogalactopyranoside (IPTG) and 100 mg/
ml ampicillin and then seeded with 125 μl of saturated
overnight culture. Q82:GFP nematode populations were
synchronized by using a hypochlorite treatment to yield
embryos. Embryos were placed on RNAi-seeded plates 2–
4 hours after seeding. Worms were removed from plates
after 24 or 48 hours for analysis. Control RNAi was per-
formed using the pL4440 empty vector in HT115.
Nematode aggregate analysis
Nematodes were fixed in methanol onto polylysine-
coated slides and mounted in Vectashield plus DAPI (4,6-
diamidino-2-phenylindole). Aggresomes were counted by
observation on a Nikon E600 microscope equipped with
a QiCam digital camera (Q Imaging). A minimum of 10
worms were analyzed for each condition. Sizes of individ-
ual aggregates were determined using Image Pro software.
At least 100 aggregates were sized for each RNAi condi-
tion. Soluble GFP was observed by anesthetizing nema-
todes with 25 mg/mL tetramisole (Sigma) in PBS.
Colocalization of ubiquitin and proteasome to aggregates
was determined using mouse-anti-ubiquitin (1:200;
P4D1 from Santa Cruz Biotechnology) and rabbit-anti-
proteasome (1:200; ab2943 from Abcam). Nematodes
were fixed with methanol onto polylysine-coated slides
and incubated in primary antibody overnight followed by
incubation with secondary antibody for 2 hours. Second-
ary antibodies were goat-anti-mouse Rhodamine and
goat-anti-rabbit Rhodamine (Jackson ImmunoResearch)
Worms were observed and analyzed using the microscopy
tools mentioned above.
Cell culture maintenance and RNA interference in HEK293 
cells
Cell culture reagents were purchased from Mediatech.
HEK293 cells were transiently transfected using Arrest-In™
transfection reagent (Open Biosystems) following the
manufacturer's protocol. Cell culture was done in DMEM
with 10% FBS in an incubator with 5% CO2.
shRNA plasmids were isolated using a Qiagen kit and ver-
ified using restriction digests. Transfections were done in
6 well plates. For each well, 2 μg of shRNA plasmid and
100 ng of Q81:YFP in 50 μl of serum free DMEM was
added to 50 μl of diluted Arrest-In™ and left at room tem-
perature for 15 min. The transfection mixture was added
drop wise to the wells and incubated at 37°C; 5% CO2.
Media was changed 1 day following transfection. Cells
were analyzed 72 hrs after transfection.
Aggregate analysis in HEK293 cells
Images were taken of cells containing fluorescent aggre-
gates 72 hrs after transfection with shRNA plasmids. Each
experiment was repeated three times and each time 150BMC Cell Biology 2007, 8:32 http://www.biomedcentral.com/1471-2121/8/32
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transfected cells were examined. The number of aggregates
per cell was counted, and area of each aggregate was meas-
ured using SPOT software (Diagnostics Instruments). Area
of aggregates was converted to μm2 by calibrating with a
micrometer (1 μm was equivalent to 39.6 pixels).
For localization of Ubc proteins in aggregate-containing
cells, HEK293 cells were cultured in 24 well plates and
transfected with 100 ng of Q81:YFP in each well. Cells
were incubated for 48 hrs, then trypsinized and trans-
ferred to 4-chambered slides (NUNC). After another 24
hrs, cells were washed once with PBS and fixed with 4%
paraformaldehyde (in PBS) at 4°C for 30 min. Cells were
checked for fixation under a light microscope. After fixa-
tion, cells were washed three times with Tris buffered
saline (TBS; 50 mM Tris, 150 mM NaCl pH 7.6) followed
by blocking (1% BSA, 0.3% Triton-X-100 in TBS) for 1 hr
at room temperature. Primary antibody (rabbit-anti-E2-
25K from Boston Biochem 1: 200 or goat-anti-Ube2A pol-
yclonal 1: 100 or goat anti-Ubch5B polyclonal 1:100 both
from Santa Cruz Biotechnology) was added in 1% BSA,
0.3% Triton-X-100 and incubated overnight at 4°C. Slides
were then washed three times with TBS followed by incu-
bation with secondary antibody (goat-anti-rabbit Rhod-
amine from Jackson ImmunoResearch or rabbit-anti-goat
Rhodamine from Open Biosystems) in 1% BSA, 0.3% Tri-
ton-X-100 and incubated for 6 hrs at 4°C in the dark.
Cells were washed three times with TBS. Chambers were
removed from the slides very carefully until no gum was
left on the slide. Prolong Gold Antifade reagent with DAPI
(Molecular Probes) was added and was allowed to cure
overnight at 4°C in dark. Cells were examined using a
Leica DMIRB inverted microscope equipped with a SPOT
RT slider color digital camera. Images were obtained with
blue, green, red fluorescence filters. Images were proc-
essed by C IMAGING software (SIMPLE PCI Inc.).
RT-PCR
Worms were grown on RNAi plates for 48 hours, collected
by centrifugation, washed 5 times with PBS, and frozen at
-80°C. Frozen pellets were ground using a mortar and pes-
tle in liquid N2. RNA extractions were performed using the
QiaShredder and RNeasy miniprep kits (Qiagen). cDNA
was synthesized from the RNA samples with the Tran-
scriptor First Strand cDNA kit (Roche) using 10 μl of RNA
as template. PCR reactions used 2 μl of cDNA and the fol-
lowing primers: UBC1F  CAAATAAACCGCCAACCGT-
CAA, UBC1R TCTCATATTCCCGTCGATTTTCTT, UBC2F
ACTTCCCAACAGACTATCCATTCA,  UBC2R  AGCG-
TACTTTTGCGTCCATTCTCT,  ACT1F  CCGCCGGAATC-
CACGAGACT,  ACT1R  GTGGAGAGGGAAGCGAGGATA
GAT.
Immunoblotting
Nematodes
Worms were grown on RNAi plates for 48 hours, collected
by centrifugation, washed with sterile water, and sus-
pended in 1× protein sample buffer with BME. Samples
were heated at 100°C for 5 minutes, resolved on 10%
SDS-polyacrylamide gels, transferred to PVDF mem-
branes, and incubated overnight with mouse anti-GFP
antibody (1:200; Santa Cruz Biotechnology) at 4°C and 1
hour at room temperature with secondary antibody
(1:10,000, Pierce) Blots were reprobed with anti-actin
antibody (1:500; C4 from Abcam) Bound antibody was
detected with SuperSignal West Pico Chemiluminescent
Substrate (Pierce). Densitometric measurements were per-
formed using Image J software.
HEK293 cells
Cells were collected from plates following trypsinization,
then washed with 1× PBS and suspended in PBS. Lysis was
done by boiling in loading buffer (50 mM Tris-HCl, pH
6.8 10% SDS, 0.1% bromophenol blue, 10% glycerol) fol-
lowed by 1 min sonication. Lysates were centrifuged at
14,000 rpm for 10 min at 4°C. Samples were electro-
phoresed through 10% SDS-polyacrylamide gels and
transferred to PVDF membranes. Membranes were probed
overnight at 4°C with using the same primary antibodies
used for immunofluorescence (dilutions: anti-E2-25K
1:1000, anti-Ube2A 1:200, anti- UbcH5b 1:200, anti-
tubulin from the Developmental Studies Hybridoma
Bank at the University of Iowa 1:1000). The secondary
antibody (goat-anti-mouse HRP or rabbit-anti-goat HRP;
Pierce) used diluted 1:10,000 and bound antibody was
detected with SuperSignal West Pico Chemiluminescent
Substrate.
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